OBJECTIVES The purpose of this study was to determine the association of complete heart block (CHB) with outcomes and to examine temporal trends in the incidence and outcomes of CHB complicating ST-segment elevation myocardial infarction (STEMI).
C omplete heart block (CHB) is a relatively frequent complication in patients hospitalized with acute myocardial infarction (AMI) (1) . Previous studies have reported the overall incidence of CHB in patients with AMI to be between 3% and 13% depending on the type and anatomical location of the AMI being investigated (2) (3) (4) (5) (6) (7) (8) . Patients who develop CHB in the setting of AMI have a 3-to 5-fold increase in in-hospital mortality compared with those without CHB (6) (7) (8) . However, most of these reports are from the pre-thrombolytic and thrombolytic era in the 1980s and 1990s, before the widespread use of percutaneous coronary intervention (PCI) and the advent of modern adjunctive medical therapies.
Data on the incidence and outcomes of CHB in patients with ST-segment elevation myocardial infarction (STEMI) in the contemporary PCI era are limited. Hence, the primary objective of this study was to examine the association of CHB with in-hospital outcomes in patients hospitalized with STEMI and to examine the temporal trends in the incidence and outcomes of CHB complicating STEMI using the National Inpatient Sample (NIS) databases from 2003 to 2012. It has been previously shown that inferior STEMI is associated with a higher incidence of CHB (6, 9) ; therefore, we also conducted subgroup analysis after stratifying patients by STEMI location to those with anterior, inferior, or other STEMI. hospitalized with the principal diagnosis of STEMI. We chose the principal diagnosis because it is considered the primary reason for hospitalization. This approach has been used by previous studies using the NIS database to accurately identify patients with STEMI (12, 13) .
Patients with pacemakers (ICD-9-CM code V45.01) or implantable cardioverter-defibrillators (ICD-9-CM code V45.02) were excluded. Patients with CHB were then identified using ICD-9-CM code 426.0.
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CABG ¼ coronary artery bypass grafting; CHB ¼ complete heart block; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-elevation myocardial infarction.
the temporal trends, we entered our independent variable (calendar year) as a continuous variable in the regression models. Then, to measure if there was a temporal variability from year to year, we also Table 3 ). Online Harikrishnan et al. Table 3) . Although STEMI patients with CHB had higher in-hospital mortality than those without CHB irrespective of the location of STEMI, the magnitude of association between CHB and higher risk-adjusted in-hospital mortality was greatest in patients with anterior STEMI. CHB was associated with an approximately 4-fold increase in mortality among patients with anterior STEMI, a 3-fold increase in mortality among patients with other STEMI, but only a 2-fold increase in mortality in patients with inferior STEMI. CHB was also associated with higher riskadjusted in-hospital mortality in STEMI patients irrespective of the treatment strategy (thrombolysis, PCI, CABG, or no reperfusion) ( Table 3 ).
In patients with CHB complicating STEMI, there was a decline in crude in-hospital mortality from 1.14 to 1.16; p < 0.001). CHB was associated with longer LOS in STEMI patients irrespective of STEMI location and treatment strategy ( Table 4) . Trend analysis showed a slight but statistically significant decrease in average LOS in patients with CHB and STEMI (Online Table 6 ).
DISCUSSION
In this large nationwide study of patients hospitalized with STEMI, we found that even in the contemporary era of prompt reperfusion therapy, CHB remains associated with significantly higher in-hospital mortality. This was true both in patients with anterior and inferior STEMI, although the absolute risk excess was significantly higher in patients with anterior STEMI.
Moreover, in patients with CHB complicating STEMI, although there were temporal declines in PPM use rates, risk-adjusted in-hospital mortality remained unchanged during the study period.
Previous studies have reported varying incidence rates of CHB complicating STEMI with more recent studies reporting lower incidence rates (2) (3) (4) (5) (6) (7) (8) 16 ). The
TAMI (Thrombolysis and Angioplasty in Myocardial
Infarction) study group reported that the incidence of CHB in 373 patients with inferior STEMI who received thrombolytic therapy was 13% (5). Data from a study in Israel that examined the incidence rates of CHB in patients hospitalized with AMI in the prethrombolytic era (1981 to 1983) compared with those hospitalized in the thrombolytic era (1992 to 1996) showed a decline in incidence rates of CHB from 5.3% to 3.7% (2). The incidence of CHB among 6,676 AMI patients screened for entry into the TRACE (Trandolapril Cardiac Evaluation) randomized trial was 5% (3) . Analysis of data from the Worcester Heart Attack Study showed that the overall incidence of CHB in 13,663 AMI patients was 4.1%, with a significant decline in CHB incidence from 1975 to 2005 (7).
In comparison, the incidence of CHB complicating STEMI in our study was 2.2%, much lower than what was observed in previously mentioned studies. This likely reflects the overall improvement in the care of STEMI patients over the years, with increasing early use of guideline-recommended invasive reperfusion strategies and adjunctive medical therapies, thus reducing ischemic time, limiting infarct size, and preserving ventricular function, all of which could potentially contribute to lower CHB incidence. In addition, because of the administrative source of our data, underreporting due to coding errors could also have contributed to the low incidence of CHB observed in our study. Although the incidence rate of CHB in our study was lower throughout the study period in comparison to that previously reported, we noted a small but statistically significant increase in the incidence rate from 2003 to 2012. This trend is difficult to explain, but is likely a result of unmeasured confounding, random variation, or more frequent diagnosis as a result of "diagnosis-related group creep" (17) (refers to changes in hospital record documentation to increase case mix and reimbursement), rather than an actual increase in incidence.
Concordant with the findings of previous studies (6,16), we found that the incidence of CHB complicating STEMI was higher patients with inferior STEMI compared with anterior or other STEMI. CHB complicating anterior STEMI is usually within the His-Purkinje system and is related to interruption of septal perfusion accompanied by extensive myocardial damage and significant left ventricular dysfunction (18, 19) . In inferior STEMI, CHB usually occurs at the atrioventricular (AV) nodal level and is usually related to hypoperfusion of the AV nodal artery, which typically arises from the right coronary artery (20) . Consistent with these observations, we found that the negative prognostic impact of CHB was greater in patients with anterior STEMI than it was in patients with inferior STEMI.
Contemporary data on the use of temporary or permanent pacing for CHB in the setting of AMI are scarce.
In the Worcester Heart Attack Study, TTVP was used in 53.6% and PPM in 10.1% of the patients with CHB and AMI (7). The GRACE (Analysis of the Global Registry of Acute Coronary Events) trial showed that TTVP was used in 35% and PPM in 5.9% of the patients with highdegree AV block (Mobitz type 2 second-degree heart block or CHB) complicating acute coronary syndromes (both ST-segment elevation and non-ST-segment elevation acute coronary syndromes), with a decline in both TTVP and PPM use rates from 1999 to 2007 (21) . In comparison, TTVP was used in 31.8% and PPM in 13.4% of the patients with CHB in our study.
Also, although PPM use declined significantly, there was no change in the use of TTVP during the study Harikrishnan et al. Values are % unless otherwise indicated. Regression models adjusted for demographics, hospital characteristics, and all comorbidities.
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Harikrishnan et al. representative of the requirement for permanent pacing alone for CHB. Seventh, some of our findings, although statistically significant, might not be clinically meaningful. Lastly, data in NIS are limited to in-hospital events, and information on long-term outcomes is not available.
CONCLUSIONS
CHB is a recognized complication in patients with STEMI and is associated with worse outcomes.
Although the incidence of CHB complicating STEMI has increased slightly over the last decade, the absolute incidence of CHB in STEMI patients receiving contemporary management is quite low. Our data show that CHB remains an adverse prognostic marker in STEMI patients in the PCI era, with the association between CHB and worse in-hospital outcomes being more significant in patients with anterior STEMI.
Despite advances in STEMI care over the last several years, in-hospital mortality associated with CHB has not declined. Hence, future investigations should focus on developing strategies to improve outcomes in patients with STEMI complicated by CHB. In the meantime, early reperfusion and adjunctive medical therapies for STEMI aimed at attenuating ischemic injury should be aggressively pursued because these could potentially affect the incidence of and outcomes associated with CHB.
